Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $8.91, but opened at $9.14. Pharming Group shares last traded at $9.25, with a volume of 752 shares trading hands.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, October 10th.
Check Out Our Latest Analysis on Pharming Group
Pharming Group Stock Up 0.3 %
The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65. The stock has a market capitalization of $606.18 million, a P/E ratio of -47.03 and a beta of 0.15. The firm has a 50-day simple moving average of $7.97 and a 200 day simple moving average of $8.58.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. During the same quarter last year, the business earned $0.02 earnings per share. On average, equities research analysts forecast that Pharming Group will post -0.15 EPS for the current year.
Hedge Funds Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 41,110 shares of the company's stock after purchasing an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by hedge funds and other institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
